Association between urinary phthalate metabolites and dyslipidemia in children: Results from a Chinese cohort study

Di Gao1, Zhiyong Zou1, Yanhui Li1

  • 1Institute of Child and Adolescent Health, School of Public Health, Peking University, Beijing, China.

Insights

Childhood exposure to phthalates, common chemicals, is linked to increased risks of dyslipidemia, a lipid disorder. Boys appear more vulnerable to these effects, highlighting a significant public health concern.

Area of Science:

  • Environmental Health
  • Pediatric Endocrinology
  • Metabolic Disorders

Background:

  • Phthalate exposure is increasingly linked to metabolic disorders.
  • Research on childhood dyslipidemia associated with phthalates is limited.
  • Phthalates are common environmental chemicals found in plastics and personal care products.

Purpose of the Study:

  • To investigate the association between phthalate metabolite exposure and dyslipidemia in Chinese children.
  • To explore dose-response relationships and identify specific phthalate metabolites of concern.
  • To examine sex-specific differences in vulnerability to phthalate exposure.

Main Methods:

  • A cohort study of 829 children in Xiamen, China, with urine and blood sample collection.
  • Follow-up assessments conducted annually from 2018 to 2020.
  • Statistical analyses included adjusted log-binomial regressions and generalized estimating equation (GEE) models.

Main Results:

  • Increased prevalence and risk of dyslipidemia correlated with higher levels of specific phthalate metabolites (MnBP, MEOHP, MEHHP, ∑DEHP).
  • A dose-response relationship was observed for dyslipidemia and persistent dyslipidemia.
  • Higher phthalate exposure was associated with elevated triglyceride levels, with boys showing greater susceptibility.

Conclusions:

  • Widespread childhood phthalate exposure in China is confirmed.
  • Childhood phthalate exposure is a significant risk factor for dyslipidemia and adverse lipid profiles, especially in boys.
  • Findings underscore the need for strategies to reduce phthalate exposure in children.

Related Concept Videos

Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
732
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
331
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
24
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
15
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
9
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
15